

DRIVE-AB

RE-INVESTMENT
IN R&D AND RESPONSIBLE
ANTIBIOTIC USE



DRIVE-AB is now on **Twitter!**

Don't be left out of the loop - follow us at [@DRIVE_AB](#).

Fill out our new [Expression of Interest Form](#) for stakeholders to let us know exactly how you or your organization would like to engage with the project. Please share this with other interested stakeholders as well!

The Newsletter

This quarterly newsletter provides all stakeholders with an overview of the activities and accomplishments of each of the DRIVE-AB work packages as well as any notable announcements. Should you wish to receive more detailed information, nominate another stakeholder or update us on your activities as relevant to the project please contact [Victoria Wells](#), DRIVE-AB Communications Officer.

What have we been up to?

DRIVE-AB has been busy expanding its reach, building its stakeholder platform, and working towards completing its project deliverables.

DRIVE-AB made a recent appearance at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2015 in Copenhagen, Denmark. The project received significant attention and was featured in the Pipeline Corner, the European Network Corner, and during the sessions "What is responsible use of antibiotics?" and "New antibiotics". DRIVE-AB was also mentioned in the regulatory session by Marco Cavaleri from the European Medicines Agency (EMA). EMA is part of DRIVE-AB's stakeholder platform. Ursula Theuretzbacher, Work Package 3B academic leader, was also interviewed by the ECCMID TV-team and by the Swedish press. DRIVE-AB posters from the congress can be



accessed on our [website](#).

Dr John Rex, Work Package 1C EFPIA co-leader, and Professor Stephan Harbarth, Work Package 3A EFPIA co-leader, presented at the Geneva Pharma Forum, "Antimicrobial resistance: Stepping up to the challenge" on April 30 this year, which was hosted by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Stephan Harbarth highlighted in his talk what we do currently know about the clinical and public health impact of AMR. The presentation "Enabling drug discovery and development to address the crisis of antibacterial resistance: New tools, new pathways and remaining challenges", given by John Rex, is a comprehensive review of how far we have come in addressing the antimicrobial resistance crisis and which challenges still face us today, and why. The complete slide sets for both presentations can be found on the [DRIVE-AB website](#).



DRIVE-AB is planning a spring 2016 mid-term conference under the umbrella of the Dutch EU presidency to discuss driving change in thinking about reinvestment and responsible use. The audience will include politicians, policy makers, and others with macroeconomic influence. The DRIVE-AB project continues to collaborate with like-minded initiatives such as the UK Review on Antimicrobial Resistance (also known as the O'Neill Commission), the US Centers for Disease Control (CDC), the Uppsala Health Summit, and the G7 Summit, among others.

Stakeholder meetings between different work packages and a wide variety of groups are planned for the remainder of 2015.

DRIVE-AB is pleased to welcome two new project participants. An updated version of the Participants List, which outlines the DRIVE-AB structure and describes all partners and participants, can be found [here](#).

Project updates by work package

For an overview of the different work packages, please visit our [website](#).

Work Package 1

WP1A: Responsible use of antibiotics, new and old

The team is continuing to work on systematic reviews of quality indicators, quantity metrics and variations of antibiotic use. They have also entered into discussions with the US Centers for Disease Control (CDC) about collaboration in activities surrounding antibiotic stewardship.

WP1B: Setting, communicating and revising public health priorities

The team is continuing data mining of bacterial resistance surveillance systems, and observed patterns will be used in mathematical modelling. WP1B is also conducting a literature review on the earliest reports and initial spread of multi-drug resistant organisms (MDRO). This review will be used to build agent-based mathematical models that represent regional and institutional spread of MDROs.

WP1C: Antibiotic Valuation

The team is finalising a first paper on the impact of resistance in health systems. Meanwhile, they are also working on a framework paper on the value of antibiotics and a paper on lessons learnt from the pre-antibiotic era.

Work Package 2

WP2: Creation and testing of new economic models

The team held its first stakeholder meeting with small and medium enterprises (SMEs) in London in February. The full report from this meeting is available on the [website](#). A brainstorming session was also held in Uppsala in April to learn from other industry models. WP2 has also organised future 2015 meetings with HTA stakeholders, the Review on Antimicrobial Resistance (O'Neill Commission), American Senators, and BARDA.

Work Package 3

WP3A: Project management and governance

WP3A is establishing a governance board for the project which will have as its main role the provision of strategic oversight. External members who have agreed to sit on this board include so far Professor Aaron Kesselheim from the Brigham and Women's Hospital and Harvard Medical School, Boston, USA and Professor Paul Tulkens from the Université catholique de Louvain and Louvain Drug Research Institute, Belgium. WP3A is organising the first General Assembly meeting in Uppsala, Sweden on October 15, 2015 which all DRIVE-AB partners will attend and have begun to plan for the first annual report to the Innovative Medicines Initiative.

WP3B: Stakeholder platform and external communication

The team has formed an official Communications Committee to oversee project-wide communications activities, in addition to managing the website, Twitter account, and collaborating with other work packages on stakeholder engagement activities. They have also developed an expression of interest form for new and existing stakeholders so that you can tell us how you would like to engage with DRIVE-AB. To fill out this short form, which will help us to ensure that you are engaged appropriately, please click [here](#). Please also share this form with others who may be interested in becoming a stakeholder.

If you wish to engage with DRIVE-AB in any specific meeting or activity described in this newsletter, please contact [Victoria Wells](#).

To find out more, visit our [website](#).

[Edit your subscription](#) | [Unsubscribe](#)